IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: Current status

Journal of Neurology, Supplement

Volumn 252, Issue 1, 2005, Pages 14-18

  Illa, Isabel ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Inflammatory myopathies; IVIg; Lambert eaton syndrome; Myasthenia

Indexed keywords

IMMUNOGLOBULIN;

DERMATOMYOSITIS; EATON LAMBERT SYNDROME; HUMAN; INCLUSION BODY MYOSITIS; MUSCLE DISEASE; MYASTHENIA GRAVIS; POLYMYOSITIS; REVIEW;

DERMATOMYOSITIS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LAMBERT-EATON MYASTHENIC SYNDROME; MUSCULAR DISEASES; MYASTHENIA GRAVIS; MYOSITIS, INCLUSION BODY; POLYMYOSITIS;

EID: 84865378641     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Achiron A, Barak Y, Miron S, SarovaPinhas I (2000) Immunoglobulin treatment in refractory Myasthenia gravis. Muscle Nerve 23:551-555 (Pubitemid 30164781)
2. Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM ( 2000) Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 27: 2498-2503
3. Arsura EL, Bick A, Brunner NG, Grob D ( 1988) Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. Am J Med Sci 295: 438-443
4. Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, Lee ML, Vincent A, Lang B ( 1996) Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 47: 678-683
5. Bird SJ ( 1992) Clinical and electrophysiologic improvement in LambertEaton syndrome with intravenous immunoglobulin therapy. Neurology 42: 1422-1423
6. Cherin P, Herson S, Wechsler B, Piette JC, Bletry O, Coutellier A, Ziza JM, Godeau P ( 1991) Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 91: 162-168
7. Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, Maisonobe T, Eymard B, Herson S (2002) Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 46:467-474 (Pubitemid 34136585)
8. Cosi V, Lombardi M, Piccolo G, Erbetta A ( 1991) Treatment of myasthenia gravis with high-dose intravenous immunoglobulin. Acta Neurol Scand 84: 81-84
9. Dalakas MC ( 1991) Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 325: 1487-1498
10. Dalakas MC ( 1998) Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology 51: S37-S45
11. Dalakas MC ( 1999) Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 22: 1479-1497
12. Dalakas MC ( 2003) Therapeutic approaches in patients with inflammatory myopathies. Semin Neurol 23: 199-206
13. Dalakas MC ( 2004) The molecular pathophysiology in inflammatory myopathies. Rev Med interne 25( Suppl 1): S14-S16
14. Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362:971-982 (Pubitemid 37159295)
15. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993-2000 (Pubitemid 24015043)
16. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E (2001) A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56:323-327 (Pubitemid 32144142)
17. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K (1997) Treatment of inclusion-body myositis with IVIg: a double-blind, placebocontrolled study. Neurology 48: 712-716 (Pubitemid 27120112)
18. Danieli MG, Malcangi G, Palmieri C, Logullo F, Salvi A, Piani M, Danieli G (2002) Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 61:37-41 (Pubitemid 34074837)
19. Drachman DB ( 1994) Myasthenia gravis. N Engl J Med 330: 1797-1810
20. Drachman DB, Jones RJ, Brodsky RA (2003) Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide. Ann Neurol 53: 29-34 (Pubitemid 36083826)
21. Fateh-Moghadam A, Wick M, Besinger U, Geursen RG (1984) High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1:848-849 (Pubitemid 14174296)
22. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C (1997) Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 41:789-796 (Pubitemid 27249184)
23. Gajdos P, Chevret S, Toyka K ( 2003) Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev: CD002277
24. Gronseth GS, Barohn RJ (2000) Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55:7-15 (Pubitemid 30460990)
25. Hoch W, McConville J, Heims S, Newsom-Davis J, Melms A, Vincent A (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365-368 (Pubitemid 32224355)
26. Hughes BW, Moro De Casillas ML, Kaminski HJ (2004) Pathophysiology of myasthenia gravis. Semin Neurol 24:21-30 (Pubitemid 38823776)
27. Lang B, Newsom-Davis J, Wray D, Vincent A, Murray N (1981) Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 2:224-226 (Pubitemid 11095446)
28. Mareska M, Gutmann L (2004) Lambert-Eaton myasthenic syndrome. Semin Neurol 24:149-153 (Pubitemid 38971841)
29. Mastaglia FL, Phillips BA, Zilko PJ (1998) Immunoglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry 65:107-110 (Pubitemid 28302366)
30. McEvoy KM, Windebank AJ, Daube JR, Low PA (1989) 3.4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 321:1567-1571 (Pubitemid 20008235)
31. Meriggioli MN, Ciafaloni E, Al-Hayk KA, Rowin J, Tucker-Lipscomb B, Massey JM, Sanders DB (2003) Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 61: 1438-1440 (Pubitemid 37463389)
32. Muchnik S, Losavio AS, Vidal A, Cura L, Mazia C (1997) Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin. Muscle Nerve 20:674-678 (Pubitemid 27197719)
33. Newsom-Davis J ( 2004) LambertEaton myasthenic syndrome. Rev Neurol (Paris) 160: 177-180
34. Palace J, Newsom-Davis J, Lecky B (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 50:1778-1783 (Pubitemid 28283251)
35. Perez Nellar J, Dominguez AM, Llorens-Figueroa JA, Ferra-Betancourt A, Pardo A, Quiala M, Gali Z (2001) A comparative study of intravenous immunoglobulin and plasmapheresis preoperatively in myasthenia. Rev Neurol 33:413-416 (Pubitemid 33647440)
36. QureshiAl, Choudhry MA, Akbar MS, Mohammad Y, Chua HC, Yahia AM, Ulatowski JA, Krendel DA, Leshner RT ( 1999) Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 52: 629-632
37. Richman DP, Agius MA ( 2003) Treatment of autoimmune myasthenia gravis. Neurology 61: 1652 -1661
38. Ronager J, Ravnborg M, Hermansen I, Vorstrup S (2001) Immunoglobulin treatment versus plasma exchatige in patients with chronic moderate to severe myasthenia gravis. Artif Organs 25:967-973 (Pubitemid 34107305)
39. Sanders DB, Massey JM, Sanders LL, Edwards LJ ( 2000) A randomized trial of 3,4-diaminopyridine in LambertEaton myasthenic syndrome. Neurology 54: 603-607
40. Takano H, Tanaka M, Koike R, Nagai H, Arakawa M, Tsuji S (1994) Effect of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome with small-cell lung cancer: correlation with the titer of anti-voltage-gated calcium channel antibody. Muscle Nerve 17:1073-1075 (Pubitemid 24271457)
41. Vincent A, Bowen J, Newsom-Davis J, McConville J (2003) Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol 2:99-106 (Pubitemid 37443330)
42. Vincent A, McConville J, Farrugia ME, Bowen J, Plested P, Tang T, Evoli A, Matthews I, Sims G, Dalton P, Jacobson L, Polizzi A, Blaes F, Lang B, Beeson D, Willcox N, Newsom-Davis J, Hoch W (2003) Antibodies in myasthenia gravis and related disorders. Ann N Y Acad Sd 998:324-335 (Pubitemid 37194175)
43. Walter MC, Lochmuller H, Toepfer M, Schlotter B, Reilich P, Schroder M, Muller-Felber W, Pongratz D (2000) High-dose immunoglobulin therapy in sporadic: inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 247:22-28 (Pubitemid 30162508)
44. Wolfe GI, Barohn RJ, Foster BM, Jackson CE, Kissel JT, Day JW, Thornton CA, Nations SP, Bryan WW, Amato AA, Freimer ML, Parry GJ ( 2002) Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 26: 549-552